Decarb Injection (200mg) is a chemotherapy medication that contains Dacarbazine as its active ingredient, primarily used in the treatment of certain types of cancer, including melanoma and Hodgkin’s lymphoma. This injectable formulation is designed to inhibit the growth of cancer cells by interfering with their DNA synthesis. Dacarbazine is classified as an alkylating agent, which means it works by adding alkyl groups to the DNA, leading to cell death. The injection is typically administered in a clinical setting under the supervision of healthcare professionals, ensuring that patients receive the correct dosage and monitoring for any adverse effects. Decarb Injection is an essential component of combination chemotherapy regimens, enhancing the overall effectiveness of cancer treatment. Its composition and mechanism of action make it a vital option for oncologists when devising treatment plans for patients battling aggressive malignancies.